CN105025901B - 他唑巴坦精氨酸抗生素组合物 - Google Patents

他唑巴坦精氨酸抗生素组合物 Download PDF

Info

Publication number
CN105025901B
CN105025901B CN201380061707.7A CN201380061707A CN105025901B CN 105025901 B CN105025901 B CN 105025901B CN 201380061707 A CN201380061707 A CN 201380061707A CN 105025901 B CN105025901 B CN 105025901B
Authority
CN
China
Prior art keywords
beta
amino
arginine
tazobactam sodium
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380061707.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105025901A (zh
Inventor
J-J·莱
J-Q·古
P·M·帕萨瑞
V·朱尔考斯卡斯
J·特拉希亚诺
N·米勒达茂尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme BV
Original Assignee
Cubist Pharmaceuticals LLC
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharmaceuticals LLC, Merck Sharp & Dohme LLC filed Critical Cubist Pharmaceuticals LLC
Publication of CN105025901A publication Critical patent/CN105025901A/zh
Application granted granted Critical
Publication of CN105025901B publication Critical patent/CN105025901B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN201380061707.7A 2012-09-27 2013-09-27 他唑巴坦精氨酸抗生素组合物 Active CN105025901B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706399P 2012-09-27 2012-09-27
US61/706,399 2012-09-27
PCT/US2013/062256 WO2014052799A1 (en) 2012-09-27 2013-09-27 Tazobactam arginine antibiotic compositions

Publications (2)

Publication Number Publication Date
CN105025901A CN105025901A (zh) 2015-11-04
CN105025901B true CN105025901B (zh) 2019-04-19

Family

ID=50389002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061707.7A Active CN105025901B (zh) 2012-09-27 2013-09-27 他唑巴坦精氨酸抗生素组合物

Country Status (12)

Country Link
US (4) US20150306076A1 (enExample)
EP (1) EP2900244B1 (enExample)
JP (1) JP6186001B2 (enExample)
KR (1) KR102143256B1 (enExample)
CN (1) CN105025901B (enExample)
AU (2) AU2013323280A1 (enExample)
BR (1) BR112015006868B1 (enExample)
CA (1) CA2886402A1 (enExample)
IN (1) IN2015DN03113A (enExample)
MX (1) MX2015004039A (enExample)
RU (1) RU2671485C2 (enExample)
WO (1) WO2014052799A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101638311B1 (ko) * 2016-02-29 2016-07-12 (주)에프원테크놀로지 3축 코일 안테나의 단자부 및 이의 제조방법
MX2017013433A (es) * 2016-03-31 2018-01-30 Wockhardt Ltd Composiciones antibacterianas.
WO2017213944A1 (en) * 2016-06-06 2017-12-14 Merck Sharp & Dohme Corp. Solid forms of ceftolozane and processes for preparing
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1236781A (zh) * 1999-01-12 1999-12-01 中国药品生物制品检定所 他唑巴坦半水合物的制备与应用
CN101287446A (zh) * 2005-09-29 2008-10-15 尼克塔治疗公司 抗生素制剂、单位剂量、试剂盒以及方法
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8323034D0 (en) * 1983-08-26 1983-09-28 Fujisawo Pharmaceutical Co Ltd 7-substituted-3-vinyl-3-cephem compounds
JP2648750B2 (ja) * 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
AU679800B2 (en) * 1993-11-06 1997-07-10 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
JP3743823B2 (ja) * 2000-08-11 2006-02-08 大塚化学ホールディングス株式会社 ペニシリン結晶及びその製造法
JP3306473B1 (ja) * 2001-05-01 2002-07-24 大塚化学株式会社 β−ラクタム化合物の無水結晶及びその製造法
JP2002338578A (ja) * 2001-05-14 2002-11-27 Otsuka Chem Co Ltd β−ラクタム化合物の水和物結晶
ATE368042T1 (de) 2002-10-30 2007-08-15 Astellas Pharma Inc Cephemverbindungen
RS51506B (sr) * 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
US20140275000A1 (en) * 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1236781A (zh) * 1999-01-12 1999-12-01 中国药品生物制品检定所 他唑巴坦半水合物的制备与应用
CN101287446A (zh) * 2005-09-29 2008-10-15 尼克塔治疗公司 抗生素制剂、单位剂量、试剂盒以及方法
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
An integrated approach to the selection of optimal salt form for a new drug candidate;Kenneth R.Morris等;《International Journal of Pharmaceutics》;19941231;209-217 *
Catharine C. Bulik等.In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms.《Antimicrobial Agents and Chemotherapy》.2011,第56卷(第1期),544-549. *
Catharine C.Bulik等.In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms.《Antimicrobial Agents and Chemotherapy》.2011,第56卷(第1期),544-549. *
In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms;Catharine C. Bulik等;《Antimicrobial Agents and Chemotherapy》;20111107;第56卷(第1期);544-549 *
Kenneth R.Morris等.An integrated approach to the selection of optimal salt form for a new drug candidate.《International Journal of Pharmaceutics》.1994,209-217. *

Also Published As

Publication number Publication date
US20140206659A1 (en) 2014-07-24
RU2671485C2 (ru) 2018-11-01
JP6186001B2 (ja) 2017-08-23
AU2018203806B2 (en) 2020-04-02
EP2900244A4 (en) 2016-05-04
BR112015006868A2 (pt) 2017-07-04
JP2015531378A (ja) 2015-11-02
MX2015004039A (es) 2015-10-29
BR112015006868B1 (pt) 2021-11-30
AU2013323280A1 (en) 2015-04-09
CN105025901A (zh) 2015-11-04
CA2886402A1 (en) 2014-04-03
US20150306076A1 (en) 2015-10-29
KR102143256B1 (ko) 2020-08-11
US20140187528A1 (en) 2014-07-03
RU2015115711A (ru) 2016-11-20
EP2900244B1 (en) 2019-10-23
EP2900244A1 (en) 2015-08-05
WO2014052799A1 (en) 2014-04-03
AU2018203806A1 (en) 2018-06-21
KR20150070156A (ko) 2015-06-24
US20140213567A1 (en) 2014-07-31
IN2015DN03113A (enExample) 2015-10-02
BR112015006868A8 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
RU2671485C2 (ru) Антибиотические композиции тазобактама аргинина
JP6870029B2 (ja) セフトロザン抗生物質組成物
US8685957B1 (en) Tazobactam arginine compositions
US20140274996A1 (en) Tazobactam and ceftolozane antibiotic compositions
WO2022198378A1 (zh) 一种质量稳定的β内酰胺酶抑制剂组合物及其用途和方法
WO2020184399A1 (ja) 抗菌用医薬組成物
US12502362B2 (en) Inhibitors of nucleotidyltransferase superfamily enzymes as antibiotics
US7091197B2 (en) Beta-lactamase inhibitor prodrug
WO2014161412A1 (zh) 一类三环喹诺酮衍生物及其制备方法和用途
KR20260061454A (ko) 항균 조성물 및 항균 약물
TW202123945A (zh) 具有抗菌作用的醫藥組成物
US20100216745A1 (en) Novel cephem compounds useful for the treatment of bacterial infections
AU2015200599A1 (en) Ceftolozane Antibiotic Compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160307

Address after: Massachusetts, USA

Applicant after: Bath Medical Ltd.

Address before: Massachusetts, USA

Applicant before: CUBIST PHARMACEUTICALS, Inc.

Effective date of registration: 20160307

Address after: New jersey, USA

Applicant after: MERCK SHARP & DOHME Corp.

Address before: Massachusetts, USA

Applicant before: Bath Medical Ltd.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220919

Address after: new jersey

Patentee after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Patentee before: MERCK SHARP & DOHME Corp.

TR01 Transfer of patent right